

The Board of Directors' of Moberg Pharma AB (publ) (reg.no. 556697-7426) (the "Company") proposal for resolution on payment of a waiver fee to the purchaser of the Company's OTC-business

Pursuant to the transaction documents entered into in connection with the divestment of the Company's OTC-business this spring, the amount that may be distributed as part of the so-called OTC-dividend is limited to the net proceeds of the purchase price after repayment of the Company's previous bond loan. The Board of Directors' proposal for a resolution on an automatic share redemption procedure in accordance with item 17 of the agenda entails that each holder of ordinary shares will in fact receive SEK 1.47 more per ordinary redemption share, than what actually fits within the net proceeds of the purchase price. The purchaser has accepted a distribution of such larger amount against receipt of a so-called waiver fee in an amount of SEK 971,439. In connection with the payment of the proposed waiver fee, the Company also intends to make a prepayment in full of the loan in the amount of USD 2.5 million that the Company incurred from the purchaser in connection with the divestment of the Company's OTC-business.

In view of the above, and in order to enable the payment of the OTC-dividend in accordance with the Board of Directors' proposal pursuant to item 17 of the agenda, the Board of Directors proposes that the Annual General Meeting resolves to approve the payment by the Company of a waiver fee in an amount of SEK 971,439 to the purchaser of the Company's OTC-business.

Stockholm in September 2019

Moberg Pharma AB (publ)

The Board of Directors